RET and non-small cell lung carcinoma: Significantly, the enhancement of this group of genes seems to make individuals vulnerable to nivolumab, irrespective of the existence of rearranged during transfection (RET) rearrangement, a well-known mutation that stimulates non-small cell lung cancer (NSCLC).